glp-1 digital health news A new oral medication has just launched in the United States. For many patients, this represents another important step forward in the treatment of obesity and metabolic disease. Unlike the injectable The GLP-1 Breakthrough: A Cardiologist's

The relative risks of complications, including progression of CKD to end-stage kidney disease (ESKD), CVD and mortality, are increased with both reduced eGFR and elevated UACR levels [1]

Exenatide showed the highest vomiting risk in network meta-analyses comparing GLP-1 medications head-to-head

The result of healthy people injecting themselves with insulin can be acute, life-threatening hypoglycaemia

Regularly consuming probiotics might also help prevent problems related to indigestion and reflux

Country Access Guide: UK, Germany, France, Nordics, South Country Access Guide: UK, Germany, France, Nordics, South Why Access Varies Across Europe If a medicine is approved by the European Medicines Agency (EMA), it should be easily accessible in all European Union countries

Broader Medicaid eligibility, gradual tapering of cost-sharing assistance, and increased transparency in drug pricing are proposed policy solutions to reduce these barriers [137], but new legislation is expected to further depress the availability of beneficial drugs, including GLP-1R agonists, reversing attempts to optimize care for those in greatest need [138]